TÜV Rheinland’s legal woes over PIP will strengthen NBs sector
This article was originally published in Clinica
Executive Summary
Now that TÜV Rheinland, the notified body of the French company found to have fraudulently manufactured and sold breast implants with inferior grade silicon content, has been cleared of any wrongdoing in the French appeal courts, what are the knock-on effects for device companies and NBs?